AAPGV: Ascentage Pharma Group Ltd P/S Multiple

Symbol and logo of brand Ascentage Pharma Group Ltd (AAPGV)

The biotech sector possesses macro-resilience, as medical progress remains independent of GDP. High R&D costs and patents create an insurmountable barrier for competitors. Changes in the price-to-sales ratio confirm these theses, and 8.50 captures the current state of the parameter. Ascentage Pharma Group (AAPGV) focuses on targeted leukemia therapy in the US and China, developing drugs to combat chemotherapy resistance.

Ascentage Pharma (AAPGV): P/S Multiple from 01/25/2025 to 11/13/2026

Metric breakdowns and analytics for Ascentage Pharma Group Ltd (AAPGV)

- current quotes and average value forecast:
Market Price ascentage.com|AAPGV - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Ascentage Pharma Group Ltd|AAPGV - Total Company Value
- balance sheet equity data:
Net Assets per Share Ascentage Pharma|AAPGV - Book Capitalization|Market Cap to Net Assets Ratio ascentage.com|AAPGV - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Ascentage Pharma Group|AAPGV - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Ascentage|AAPGV - Company Total Debt|Debt to Book Capital Ascentage Pharma Group Ltd|AAPGV - Company Long-Term Debts|Company Short-Term Debts Ascentage Pharma|Critical Liquidity ascentage.com
- net income and valuation ratios data:
AAPGV - Net Profit|Expected Net Profit Ascentage Pharma Group|AAPGV - Price to Earnings Ratio|Future Price to Earnings Multiple Ascentage Pharma Group International|AAPGV - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Ascentage Pharma Group Ltd|AAPGV - Operating profit EBITDA|Earnings per share for the trailing year Ascentage Pharma|AAPGV - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth ascentage.com|AAPGV - Earnings per share growth in current year|Expected earnings per share trend next year Ascentage Pharma Group
- issuer revenue and sales details:
AAPGV - Company Revenue|Company Future Sales Volume ascentage.com|AAPGV - P/S Multiple|Forward P/S Multiple Ascentage Pharma Group Ltd
Summary company analytics:ascentage.com
Mass-produced product of ascentage.com

For Ascentage Pharma Group (AAPGV), whose potential in oncohematology is confirmed by international recognition, the P/S market multiple serves as an indicator for valuing future cash flows relative to current sales. This ratio is calculated as the relationship between market capitalization and annual revenue, allowing investors to determine whether the business is overvalued or to identify undervalued assets within the context of the company's therapeutic prospects.

Competing companies

ONC - Price to Sales|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|AAPG - Price-to-Revenue Ratio|Price-to-Revenue Coefficient CG Oncology Therapeutics CGON|URGN: P/S Multiple|Market Cap to Revenue bicara.com|PSNL (Personalis) - P/S Multiple|Price to Sales Erasca Inc ERAS|Price-to-Revenue Ratio Delcath (DCTH)|Y-mAbs Corp - Market Cap to Revenue Ratio|Aura Biosciences, Inc. - Market Cap to Revenue|Market Cap to Sales Volume CADL (Candel Therapeutics Inc.)|Accuray - P/S Multiple|SLS - P/S Multiple|ACTU: P/S Multiple|Price-to-Revenue Multiple Citius Oncology Inc CTOR|HURA (TuHURA Biosciences Inc.) - P/S Multiple|Price to Sales protaratx.com TARA|Market Cap to Revenue FATE (Fate Therapeutics)|WHWK (aadibio.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TScan Therapeutics, Inc. TCRX|CSBR (Champions Oncology Inc) - Price-to-Sales Ratio|XBiotech USA - P/S Multiple|Market Capitalization-to-Revenue Ratio CVM (CEL-SCI Corporation)|OSTX: P/S Multiple|radiopharmtheranostics.com (RADX) - P/S Multiple|Price-to-Revenue Ratio Artiva Biotherapeutics Inc.|ANL: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Veru Inc. (VERU)|Market Cap to Revenue tempesttx.com TPST|P/S Multiple XLO (Xilio Therapeutics)|P/S Multiple Renovaro Biosciences RENB|MURA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KAPA (Kairos Pharma Ltd)|OKUR: P/S Multiple|Price-to-Revenue Multiple CytoMed Therapeutics Limited GDTC|Price-to-Revenue Ratio Curis Inc.|APLM: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tharimmune Corp (THAR)|ADVB - Price to Sales|Genprex, Inc. - Market Cap to Revenue|P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Revenue Ratio|Price-to-Sales Ratio XBIO|SLRX: P/S Multiple|Kitov Pharma (PPBT) - P/S Multiple|AONC (American Oncology Network Inc) - P/S Multiple|P/S Multiple beigene.com|Price-to-Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|ELEV: Price-to-Sales Ratio|P/S Multiple ICAD (iCAD)|Price-to-Revenue Multiple Ikena Oncology Inc.|NTBL: Market Cap to Revenue|VIRX: Price-to-Revenue Ratio|MOR: P/S Multiple|Market Cap to Revenue NAYA Biosciences Inc